Helus Pharma Appoints Pharma Veteran Michael Cola as CEO to Lead Commercialization Push

summarizeSummary

Helus Pharma, operating as Cybin Inc., has appointed Michael Cola, a seasoned pharmaceutical executive with extensive experience in neuroscience and global commercialization, as its new CEO. This strategic hire aims to guide the company through its critical late-stage clinical development and prepare for commercial scale-up.

check_boxKey Events

• New CEO Appointment

  Helus Pharma announced the appointment of Michael Cola as Chief Executive Officer, effective immediately.

• Highly Experienced Leader

  Mr. Cola brings over 30 years of experience across neuroscience, rare disease, and specialty pharmaceuticals, including senior leadership roles at Shire PLC (where he built the multi-billion dollar Vyvanse franchise) and Astra-Merck.

• Strategic Timing for Pipeline Advancement

  The appointment comes as Helus Pharma advances its pipeline, with expected Phase 2 data for HLP004 this quarter and Phase 3 topline data for HLP003 in Q4 2026. HLP003 has Breakthrough Therapy Designation.

auto_awesomeAnalysis

Helus Pharma's appointment of Michael Cola as CEO is a significant positive development, particularly given his extensive background in neuroscience, global commercialization, and capital formation. His track record at Shire PLC, where he helped scale the company into a CNS leader and built a multi-billion dollar franchise, is highly relevant for Helus Pharma as it transitions from early clinical development to later-stage execution. With key Phase 2 and Phase 3 data readouts expected this year for HLP004 and HLP003 (which has Breakthrough Therapy Designation), Mr. Cola's expertise in guiding assets through development and into global markets is crucial for maximizing the commercial potential of the pipeline and securing necessary funding.